105 related articles for article (PubMed ID: 9413708)
1. Metrifonate. A viewpoint.
Taylor P
Drugs Aging; 1997 Dec; 11(6):497. PubMed ID: 9413708
[No Abstract] [Full Text] [Related]
2. Metrifonate. A viewpoint.
Giacobini E
Drugs Aging; 1997 Dec; 11(6):497. PubMed ID: 9413707
[No Abstract] [Full Text] [Related]
3. Metrifonate: update on a new antidementia agent.
Ringman JM; Cummings JL
J Clin Psychiatry; 1999 Nov; 60(11):776-82. PubMed ID: 10584768
[TBL] [Abstract][Full Text] [Related]
4. [Alzheimer disease. Irreversible AChE inhibition with metrifonate].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1998 Aug; 21(8):250. PubMed ID: 9758555
[No Abstract] [Full Text] [Related]
5. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Sandson TA
Neurology; 1999 Feb; 52(3):675-6. PubMed ID: 10025821
[No Abstract] [Full Text] [Related]
6. Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Knopman DS
Neurology; 1998 May; 50(5):1203-5. PubMed ID: 9595961
[No Abstract] [Full Text] [Related]
7. Effect of metrifonate on blood cholinesterases in children during the treatment of schistosomiasis.
Davis RP; Bailey DR
Bull World Health Organ; 1972; 46(6):747-59. PubMed ID: 4538536
[TBL] [Abstract][Full Text] [Related]
8. [Results of the schistosomicidal activity of an organophosphorus compound, metrifonate, in urinary bilharziasis].
Gentilini M; Danis M; Houenassou P; Arnaud JP
Bull Soc Pathol Exot Filiales; 1973; 66(2):299-306. PubMed ID: 4209135
[No Abstract] [Full Text] [Related]
9. Evaluating response to metrifonate.
Tariot PN
J Clin Psychiatry; 1998; 59 Suppl 9():33-7. PubMed ID: 9720485
[TBL] [Abstract][Full Text] [Related]
10. Metrifonate: overview of safety and efficacy.
Cummings JL
Pharmacotherapy; 1998; 18(2 Pt 2):43-6; discussion 79-82. PubMed ID: 9543464
[TBL] [Abstract][Full Text] [Related]
11. Metrifonate for Alzheimer's disease patients.
Schneider LS
J Clin Psychiatry; 2000 Mar; 61(3):218-9. PubMed ID: 10817111
[No Abstract] [Full Text] [Related]
12. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
McKeith IG
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease.
Schmidt BH; Heinig R
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():15-9. PubMed ID: 9718230
[TBL] [Abstract][Full Text] [Related]
14. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
15. Metrifonate.
Lamb HM; Faulds D
Drugs Aging; 1997 Dec; 11(6):490-6. PubMed ID: 9413706
[No Abstract] [Full Text] [Related]
16. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
Alzheimer Dis Assoc Disord; 1998 Mar; 12(1):54-7. PubMed ID: 9539412
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacology of metrifonate.
Jann MW
Pharmacotherapy; 1998; 18(2 Pt 2):55-67; discussion 79-82. PubMed ID: 9543466
[TBL] [Abstract][Full Text] [Related]
18. Metrifonate: a new agent for the treatment of Alzheimer's disease.
Williams BR
Am J Health Syst Pharm; 1999 Mar; 56(5):427-32. PubMed ID: 10096702
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
Alzheimer Dis Assoc Disord; 1996; 10(3):124-31. PubMed ID: 8876775
[TBL] [Abstract][Full Text] [Related]
20. Urinary schistosomiasis in Egyptian farmers treated with metrifonate (Bilarcil).
Farid Z; Bassily S; Kilpatrick ME; el-Masry NA; Watten RH; Trabolsi B
Ann Trop Med Parasitol; 1981 Aug; 75(4):459-61. PubMed ID: 7305511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
